Epatite B - Siematologia

Vai ai contenuti

Menu principale:

Epatite B

LINEE GUIDA > Linee Guida > capitolo10
infezioniLG10
infezionilg10-1-3-1
Raccomandazioni del Panel SIE TUTTI i Pazienti in trattamento steroideo Immunosoppressivo,... REFERENZE >> HBV-DNA- HBV-DNA+ HBsAg-&HBcAb+ HBsAg-&HBcAb- HBsAg+ SCREENING 1° Livello: HBcAb, HBsAg, GOT, GPT, ALP, GGT, Br+...
 
The SIE Experts recommend front-line antiviral prophylactic drugs for HBsAg-positive patients who are included in all risk groups for reactivation (universal prophylaxis).
 
EASL Clinical Practice Guidelines (Journal of Hepatology 2012; 57: 167-185) and A.I.S.F. (Digestive and Liver Disease 2007; 39: 397-408)
 
The SIE Experts recommend use of antiviral drugs with a high barrier to resistance (Entecavir 0.5 mg orally every day; or Tenofovir disoproxil 245 mg orally every day) over lamivudine for prophylaxis against HBV in HBsAg-positive patients belonging to all risk groups of reactivation.
 
AGA guideline (Gastroenterology 2015; 148: 215–219), EASL Clinical Practice Guidelines (Journal of Hepatology 2012; 57: 167-185), A.I.S.F. (Digestive and Liver Disease 2007; 39: 397-408), and He Huang et al (JAMA 2014; 312:2521-2530).
Torna ai contenuti | Torna al menu